Status:
UNKNOWN
The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions
Lead Sponsor:
University Hospitals Cleveland Medical Center
Conditions:
Allergic Rhinitis
Asthma
Eligibility:
All Genders
5+ years
Phase:
PHASE1
PHASE2
Brief Summary
Subcutaneous allergen immunotherapy (SCIT) is a widely used and effective treatment modality for allergic rhinoconjunctivitis and asthma. SCIT starts with a build-up phase during which a patient recei...
Detailed Description
Subcutaneous allergen immunotherapy (SCIT) is a widely used and effective treatment modality for allergic rhinoconjunctivitis and asthma. SCIT starts with a build-up phase during which a patient recei...
Eligibility Criteria
Inclusion
- include individuals ages 5 and greater at Allergy/Immunology Associates, Inc., who are receiving build-up SCIT to tree, grass, and/or weed pollens for allergic rhinitis, allergic conjunctivitis, and/or asthma
Exclusion
- are in maintenance phase of SCIT
- are on beta-blockers
- have a forced expiratory volume in 1 second (FEV1) of less than 70% of predicted
- have a history of anaphylaxis with previous SCIT to aeroallergens (as defined by the requirement of intramuscular or subcutaneous epinephrine for treatment of a SCIT-induced reaction)
- have any uncontrolled cardiac or pulmonary disease as determined by their treating allergist/immunologist
- are pregnant, due to risk of harm to fetus if anaphylaxis occurs.
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2014
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT01878929
Start Date
April 1 2013
End Date
April 1 2014
Last Update
June 17 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergy/Immunology Associates Inc.
South Euclid, Ohio, United States, 44121